Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

  • End date
    Aug 31, 2023
  • participants needed
  • sponsor
    Institute of Hematology & Blood Diseases Hospital
Updated on 12 May 2022
ejection fraction
cell transplantation


Measurable disease (MRD) plays an important role in the therapeutic efficacy and prognosis of acute myeloid leukemia (AML). Studies show that persistent MRD positivity after induction indicates that the patient has a higher risk of recurrence. Even if the patient is assessed as a low risk group, once there is persistent MRD positive, Allogeneic hematopoietic stem cell transplantation (allo HSCT) or clinical trials should be considered to improve the overall survival of patients. However, some patients cannot accept allo HSCT due to economic reasons or lack of suitable donors. How to prolong the recurrence free survival of these patients is still a great challenge. Platzbecker et al. applied azacytidine (AZA) monotherapy to AML patients with continuous MRD positive after combined chemotherapy. The results showed that the preemptive treatment of AZA could prevent or significantly delay the hematological relapse of MDS or AML patients with MRD positive. In addition, the application of venetoclax has significantly changed the therapeutic prospect of AML and provided new opportunities. Studies have shown that venetoclax can enhance the activity of anti HMA, cytarabine, idarubicin and other drugs. The curative effect of venetoclax combined with AZA in the treatment of elderly AML patients who are not suitable for intensive treatment is better than that of single AZA regimen, and the negative rate of MRD after induction treatment of venetoclax combined with HMA is higher (54-81%). Therefore, the investigators believe that for patients who continue to be MRD positive after induction and consolidation treatment, venetoclax based regimen may be an effective preemptive treatment regimen, which can prolong the relapse free time and overall survival of these patients


In the study, 40 patients will be enrolled and treated with venotoclax combined AZA and DA regimen. Patients receive major response will be given venotoclax combined AZA regimen as maintenance treatment. The primary endpoint was 6 month relapse-free survival. Measurable residual disease (MRD) will be detected at the beginning of the therapy and after the therapy. The adverse effect will also be explored.

Preemptive chemotherapy: regimen 1: azacytidine 75 mg/m2 d1-7,venetoclax: 100mg d1, 200mg d2, 400mg d3-21; regimen 2: daunorubicin:45mg/m2 d1-2, cytarabine:100mg/ m2 d1-5, venetoclax: 100mg d1, 200mg d2, 400mg d3-14; maintenance therapy: patient in regimen 1 group: azacytidine 75 mg/m2 d1-7,venetoclax: 400mg d1-14, for 4 cycles, patients in regimen 2 group: azacytidine 75 mg/m2 d1-7,venetoclax: 400mg d1-14, for 4 cycles.

Condition Acute Myeloid Leukemia, Measurable Disease
Treatment Venetoclax, Azacitidine, Venetoclax, daunorubicin, cytarabine
Clinical Study IdentifierNCT05361057
SponsorInstitute of Hematology & Blood Diseases Hospital
Last Modified on12 May 2022


Yes No Not Sure

Inclusion Criteria

Diagnosed acute myeloid leukemia
Received chemotherapy within 24 months and has completed the consolidation treatment plan
In complete remission
With MRD positive: abnormal myeloid cells in bone marrow ≥ 0.1%, or NPM1 gene mutation and other fusion gene positive(RUNX 1-RUNX1T 1、CBFB-MYH11 and DEK-NUP214), the PCR quantification ≥1%
Age≥ 18 years #male or female
ECOG-PS score 0-2
Aboratory tests within 7 days before chemotherapy 1). Serum total bilirubin≤1.5xULN 2). Serum AST and ALT≤2.5xULN 3). Serum creatinine≤2xULN 4). Cardiac enzymes≤2xULN 5). Ejection fraction >50% by ECHO#
Written informed consent

Exclusion Criteria

Hematological relapse (the proportion of blast cells in bone marrow is greater than 5%)
Receive hematopoietic stem cell transplantation within 4 weeks
Have been treated with venetoclax in the past 6 months (who can be enrolled after stopping for more than 6 months)
Suffering from malignant tumors of other organs (those requiring treatment)
Pregnant or lactating women
Active heart diseases
Severe active infection
Unfit for enrollment evaluated by investigator
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note